Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080310 | 0.94 | MAOB (0.61) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6213004 | 0.92 | APP (0.60) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL27367676 | 0.85 | LMNA (0.82) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL339813 | 0.85 | LMNA (0.82) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL28185132 | 0.85 | MEN1 (0.59) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL14786201 | 0.83 | MAOB (0.71) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL14786200 | 0.83 | MAOB (0.71) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6957200 | 0.83 | MAOB (0.47) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL2641399 | 0.82 | LMNA (0.60) | MAOBLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6209659 | 0.82 | MAOB (0.57) | MAOBMAOANR4A2BCHEGSTP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598425-B2 | Method for preparing Ibrutinib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-21 | — | — | US | claimed |
| US-20160264584-A1 | Method for Preparing Ibrutinib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2016-09-15 | — | — | US | claimed |
| US-9249116-B2 | Enzyme-activating compounds and compositions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-02 | — | — | US | claimed |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-07-30 | — | — | US | claimed |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | claimed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | claimed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | claimed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| WO-1998025949-A1 | SUBSTITUTED 5-AMINO-1,3,4-THIADIAZOLE-2-THIONES | PROSCRIPT, INC. (US) | 1998-06-18 | — | — | WO | claimed |
| EP-0845002-A2 | AMINO ACID AMIDES OF 5-AMINO-1,3,4-THIADIAZONES AND THEIR USE AS INHIBITORS FOR MATRIX METALLOPROTEINASES | PROSCRIPT, INC. (US) | 1998-06-03 | — | — | EP | claimed |
| US-5677282-A | ENZYME INHIBITOR; OSTEOARTHRITIS AND RHEUMATIC DISORDERS | PROSCRIPT, INC. (US) | 1997-10-14 | — | — | US | claimed |
| WO-1996040745-A2 | AMINO ACID AMIDES OF 5-AMINO-1,3,4-THIADIAZONES AND THEIR USE AS INHIBITORS FOR MATRIX METALLOPROTEINASES | PROSCRIPT, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0598756-B1 | ESTER COMPOSITION | SHELL INT RESEARCH (NL) | 1996-06-05 | — | — | EP | claimed |
| US-4483861-A | Antihypertensive sulfur-containing compounds | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1984-11-20 | — | — | US | claimed |
| EP-0075629-A1 | Imidazole derivatives, their preparation, and their pharmaceutical compositions | Sumitomo Chemical Industries Ltd. (JP) | 1983-04-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264584-A1 | Method for Preparing Ibrutinib | BTK, PIM1, PIM2 | MAOB 2004/4885LMNA 2499/4885CYP1A2 817/4885 |
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | MAOB 3413/4885LMNA 3318/4885CYP1A2 3071/4885 |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | CASP3, BAX, CASP5 | MAOB 1592/4885LMNA 1013/4885CYP1A2 2681/4885 |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | MAOB 1120/4885LMNA 2624/4885CYP1A2 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.